HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS

This article was originally published in The Rose Sheet

Executive Summary

As President and CEO Peter Dolan takes helm May 1, one of his initial charges will be divesting Clairol as part of strategy to fund biologic products acquisitions. Bristol-Myers Squibb is rumored to have received bids from Procter & Gamble and Kao (1see story, p. 6). Exec also is expected to focus on building Bristol's international business, particularly in Europe and Japan. Dolan, who was appointed president and member of the board in January 2000, succeeds retired Chairman Charles Heimbold. Acquisition growth strategy and Clairol divestiture were announced by Bristol in September (2"The Rose Sheet" Oct. 2, 2000, p. 3)

Related Content

UsernamePublicRestriction

Register

RS009189

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel